At the World Without Disease Summit next month, Infinant Health CEO Mike Johnson will discuss his company’s unique insights into the infant microbiome.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.